Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. DuBrock (Rochester, United States of America), R. Channick (Los Angeles, United States of America), N. Kim (La Jolla, United States of America), V. Mclaughlin (Ann Arbor, United States of America), P. Agron (South San Francisco, United States of America), S. Leroy (Allschwil, Switzerland), G. Wetherill (Allschwil, Switzerland), K. Chin (Dallas, United States of America). Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry. 1464

Member's Comments

No comment yet.

Related content which might interest you: Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Outcome of candidates for liver transplantation suffering from portopulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Efficacy and safety of bosentan in portopulmonary hypertension according to the severity of liver disease Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Sildenafil for patients with portopulmonary hypertension, candidates to hepatic transplant Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension Source: Eur Respir J 2004; 24 : 703-707 Year: 2004 Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience Source: Eur Respir J, 53 (2) 1801096; 10.1183/13993003.01096-2018 Year: 2019 Resolution of portopulmonary hypertension (POPH) following liver transplantation Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Efficacy and safety of tadalafil in portopulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010